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INTRODUCTION
Recombinant BCG (rBCG) has been developed as a candidate neo-
natal vaccine vector against pertussis, measles, respiratory syncytial 
virus, and breast milk HIV transmission.1–5 BCG as a vaccine vector 
has many attractive features such as: (i) it has a proven record of 
safety as a vaccine against tuberculosis from its use in over two bil-
lion individuals; (ii) it infects and colonizes macrophages and den-
dritic cells, where it can survive and replicate for a long period of 
time; (iii) it can induce long-lasting humoral and cellular immune 
responses; (iv) it can be given at or any time after birth and is not 
affected by maternal antibodies; (v) manufacturing of BCG-based 
vaccines is inexpensive; and finally, (vi) it is one of the most heat-
stable vaccines in current use.6–9 
There is strong evidence in favor of a role for HIV-1–specific T-cell 
responses in the control of HIV-1 replication.10,11 One promising 
approach for T-cell induction is Mycobacterium bovis BCG as a bacte-
rial live recombinant vaccine vehicle. Specific humoral and cellular 
immune responses against HIV-1 have been detected after immuni-
zation of mice with rBCG-expressing HIV-1 antigens.12–18
Antibiotic resistance genes have been traditionally used for 
the selection and maintenance of recombinant plasmids in hosts 
such as Escherichia coli. Several approaches have been pursued 
to replace antibiotics as selective markers for plasmid stabil-
ity in bacteria, including systems using auxotrophic markers 
based on complementation of a mutation or deletion in the host 
chromosome.
In this study, we assembled a novel E. coli–mycobacterial shut-
tle plasmid p2auxo.HIVA, expressing the HIVA immunogen.19 This 
shuttle vector employs an antibiotic resistance-free mechanism 
for plasmid selection and maintenance based on glycine comple-
mentation in E. coli and lysine complementation in Mycobacteria. 
This shuttle plasmid was first transformed into glycine auxotroph 
of E. coli M15ΔglyA strain,20 as well as into lysine auxotroph of BCG 
strain to generate vaccine BCG.HIVA2auxo. The resulting antibiotic 
marker-less BCG.HIVA2auxo strain was genetically and phenotypi-
cally characterized. The presence of HIVA gene sequence and 
protein expression by the rBCG were confirmed, its safety was 
evaluated by monitoring the body mass gain, and the induction 
of HIV-1 and Mtb-specific immune responses was demonstrated 
in adult BALB/c mice after BCG.HIVA2auxo prime and modified vac-
cinia virus Ankara (MVA).HIVA boost. The BCG.HIVA2auxo strain was 
developed in good laboratory practice–compatible conditions 
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In this study, we have engineered a new mycobacterial vaccine design by using an antibiotic-free plasmid selection system. We 
assembled a novel Escherichia coli (E. coli)–mycobacterial shuttle plasmid p2auxo.HIVA, expressing the HIV-1 clade A immunogen 
HIVA. This shuttle vector employs an antibiotic resistance-free mechanism for plasmid selection and maintenance based on glycine 
complementation in E. coli and lysine complementation in mycobacteria. This plasmid was first transformed into glycine auxotroph 
of E. coli strain and subsequently transformed into lysine auxotroph of Mycobacterium bovis BCG strain to generate vaccine BCG.
HIVA2auxo. We demonstrated that the episomal plasmid p2auxo.HIVA was stable in vivo over a 7-week period and genetically and 
phenotypically characterized the BCG.HIVA2auxo vaccine strain. The BCG.HIVA2auxo vaccine in combination with modified vaccinia virus 
Ankara (MVA). HIVA was safe and induced HIV-1 and Mycobacterium tuberculosis-specific interferon-γ-producing T-cell responses in 
adult BALB/c mice. Polyfunctional HIV-1-specific CD8+ T cells, which produce interferon-γ and tumor necrosis factor-α and express 
the degranulation marker CD107a, were induced. Thus, we engineered a novel, safer, good laboratory practice–compatible BCG-
vectored vaccine using prototype immunogen HIVA.  This antibiotic-free plasmid selection system based on “double” auxotrophic 
complementation might be a new mycobacterial vaccine platform to develop not only recombinant BCG-based vaccines expressing 
second generation of HIV-1 immunogens but also other major pediatric pathogens to prime protective response soon after birth. 
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and properly characterized. In particular, it was shown to be sta-
ble in vivo, inducing specific HIV-1 and Mtb immune responses in 
adult mice and was well tolerated in mice. In addition, the com-
patibility with good laboratory practice requirements is relevant 
to upgrade this novel vaccine into clinical evaluation.
ReSUlTS
Construction of the BCG.HIVA2auxo vaccine strain
The chimeric 19-kDa signal sequence-HIVA gene was expressed from 
E. coli–mycobacterial shuttle plasmid p2auxo.HIVA under the control 
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HIVA is a replicative (multicopy, extrachromosomal) vector that con-
tains a DNA cassette encoding an E. coli origin of replication (oriE) 
and a mycobacterial plasmid DNA origin of replication (oriM). It also 
contains the wild-type glycine A-complementing gene (glyA) and 
lysine A-complementing gene (lysA5) for the vector maintenance in 
the E. coli and BCG auxotroph strain, respectively.5 Then, the antibi-
otic-free plasmid p2auxo.HIVA was transformed into glycine auxo-
troph of E. coli M15∆glyA host strain and lysine auxotroph of BCG 
host strain Pasteur ∆lysA5::res.20,21 The selection of positive recombi-
nant E. coli colonies was made by growing the E. coli transformants 
on minimal M9-D agar plates, and the BCG.HIVA2auxo colonies selec-
tion was made by growing the BCG transformants on Middlebrook 
agar 7H10 medium with no supplementation of lysine. Expression of 
the full-size chimeric 19-kDa signal sequence-HIVA protein was con-
firmed by immunodot and western blot analysis. As shown in Figure 
1b, the highest level of HIVA protein expression was detected after 
blotting the BCG culture from clone number 2 and was selected for 
further molecular characterization, immunogenicity, and safety test-
ing in mice. The BCG.HIVA2auxo clone 2 culture was preserved by using 
the seed-lot system. The expression level of HIVA protein was also 
assessed by western blot analysis. The levels of expression were com-
pared with rBCG-expressing HIVA.GFP protein and harboring the 
pJH222 E. coli–mycobacterial shuttle plasmid that contains the kana-
mycin resistance gene as a selectable marker. As shown in Figure 
1c, the level of HIVA protein expression, was similar in rBCG carry-
ing episomal p2auxo.HIVA plasmid (antibiotic-free system selection) 
in comparison with rBCG carrying the episomal pJH222.HIVAGFP 
plasmid harboring the kanamycin resistance gene. No HIVA protein 
expression was detected in BCG wild type. For future experiments, 
we will use the recently constructed BCG strain harboring the p2auxo 
plasmid DNA without heterologous insert (BCG.empty2auxo) as nega-
tive control. Growth of the transformed mycobacteria and the in vivo 
stability of p2auxo.HIVA episomal plasmid were established by the 
recovery of BCG.HIVA2auxo colonies from the spleens of BALB/c mice 
7 weeks after immunization. Ten out of 10 recovered rBCG colonies 
were positive for HIVA and E. coli glyA DNA coding sequence by poly-
merase chain reaction (PCR; Figure 1d). After DNA sequence analysis 
of the PCR products purified from two different rBCG colonies, we 
observed that the HIVA DNA sequences were identical to predictive 
DNA sequence. Thus, no mutations and genetic rearrangements 
were observed in the HIVA gene (data not shown). 
Genetic characterization of the BCG.HIVA2auxo
In order to confirm that our BCG.HIVA2auxo vaccine strain corresponds 
to BCG Pasteur substrain, we have used the multiplex PCR assay 
described by Bedwell et al.22 We tested the following samples: BCG.
HIVA2auxo strain (clone 2) lys auxotroph of BCG Pasteur, BCG wild-type 
Pasteur, commercial BCG Connaught, and BCG Danish 1331 strain. 
The PCR fingerprints of BCG Pasteur, BCG Connaught, and BCG 
Danish substrains were consistent with previously published results 
on genetic information of BCG substrains,22 and the PCR fingerprints 
of BCG.HIVA2auxo strain corresponds to BCG Pasteur substrain (data 
not shown).
For the molecular characterization of p2auxo.HIVA plasmid DNA, 
enzymatic restriction and PCR analysis were performed. The plas-
mid DNA was isolated from the master seed and working vaccine 
stock of BCG.HIVA2auxo strain and was characterized. The enzymatic 
restriction pattern obtained did not show any difference with the 
enzymatic pattern of the plasmid DNA sequence isolated from E. 
coli (pre-BCG transformation; Figure 2a). The PCR analysis using 
specific primers for the HIVA and E. coli glyA DNA coding sequences 
was performed using the BCG.HIVA2auxo master seed and working 
vaccine stocks as templates. A band of 1,776 and 1,760 bp corre-
sponding to HIVA and E. coli glyA DNA fragment, respectively, were 
detected (Figure 2b,c).
Phenotypic characterization of the BCG.HIVA2auxo
We assessed the phenotype stability of glycine and lysine auxotro-
phy, glycine and lysine complementation, and kanamycin sensitiv-
ity of E. coli M15ΔglyA strain and BCG.HIVA2auxo strains. The E. coli 
glycine auxotrophic strain failed to grow on nonglycine-supple-
mented agar plates, while growing on agar plates supplemented 
with glycine. As expected, complementation of E. coli M15∆glyA 
strain with glyA gene abolished the requirement for exogenous 
glycine. Also, when E. coli M15∆glyA strain was plated out on agar 
plates containing kanamycin, no colonies were observed, confirm-
ing the lack of kanamycin resistance in our construct. As expected, 
BCG lysine-auxotrophic strain failed to grow on nonlysine-supple-
mented agar plates, while growing on agar plates supplemented 
with lysA. Moreover, complementation of BCG.HIVA2auxo strain with 
lysine gene abolished the requirement for exogenous lysine. In 
addition, when BCG.HIVA2auxo strain was plated on agar plates con-
taining kanamycin, no colonies were observed, confirming the lack 
of kanamycin resistance in our construct (data not shown).
In vitro stability analysis of the BCG.HIVA2auxo strain
To evaluate the in vitro stability of the p2auxo.HIVA plasmid DNA 
harboring the auxotrophic complementation lysA gene, subcul-
tures on media with and without selection were carried out. All BCG.
HIVA2auxo colonies that were grown on selective medium (without 
lysine supplementation) maintained the vector for over four subcul-
tures (~30 bacterial generations). In contrast, when bacteria were 
grown without selective pressure (with lysine supplementation), 
only 9% of the BCG colonies were harboring the plasmid DNA after 
the first subculture with an average of 17% maintenance over the 
subsequent subculturing passages. The differences between both 
groups were statistically significant (P < 0.05; Figure 3a).
To assess the functional stability of the HIVA gene harbored by 
p2auxo.HIVA plasmid, the HIVA protein expression was tested by 
dot-blot analysis. When bacteria were grown under selective pres-
sure, the HIVA protein expression was detected in five out of five 
BCG.HIVA2auxo colonies and the level of expression remained stable 
Figure 1 Construction of the BCG.HIVA2auxo vaccine strain. (a) A synthetic GC-rich HIVA gene was fused to the region encoding the 19-kDa lipoprotein 
signal sequence and inserted into the episomal pJH222.HIVA E. coli–mycobacterium shuttle plasmid. The BALB/c mouse T-cell and MAb-Pk epitopes 
used in this study are depicted. P α-Ag, Mycobacterium tuberculosis α-antigen promoter; PHSP60, heat shock protein 60 gene promoter. The aph gene 
was removed by SpeI digestion, and the structural glyA gene was inserted and transformed into E. coli M15ΔglyA strain. (b) Immunodot of BCG.HIVA2auxo 
lysates. Lanes 1–4: clones 1–4 of BCG.HIVA2auxo. Lane 5: BCG wild type (negative control). Lysates of BCG.HIVA-GFP222 were used as positive control. 
(c) Western blot of BCG.HIVA2auxo lysates. Lanes 1 and 2: BCG.HIVA2auxo master seed and working vaccine stock, respectively; Lane 3: BCG wild type 
(negative control); Lane 4: BCG.HIVA-GFP222 (pJH222 E. coli–mycobacterial shuttle plasmid, kanamycin resistance) used as a positive control. (d) In vivo 
plasmid stability of BCG.HIVAauxo harboring p2auxo.HIVA. Lanes 2–7 and 9–12: 10 rBCG colonies were recovered in the nonlysine-supplemented plate; 
lanes 1 and 16: molecular weight marker; lane 8: plasmid DNA positive control (pQEαβT1FucA and pJH222.HIVA plasmid DNA); lanes 13 and 14: BCG 
wild type; lane 15: distilled water (negative control). 
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in four out of five colonies after four subcultures. To confirm that 
lack of HIVA protein expression in bacteria that were grown without 
selective pressure was due to plasmid loss, 20 colonies were cul-
tured on selective and nonselective medium. No protein expression 
was observed in five out of five colonies that were grown with lysine 
supplementation but not without lysine supplementation after four 
subcultures (Figure 3b).
Structural stability of the p2auxo.HIVA plasmid DNA was evalu-
ated by PCR analysis and restriction enzyme digestion pattern. When 
bacteria were grown under selective pressure, the PCR band corre-
sponding to HIVA DNA coding sequence was detected in five out of 
five BCG.HIVA2auxo colonies. Conversely, when bacteria were grown 
without selective pressure, the PCR and the plasmid DNA extraction 
were negative in five out of five colonies that were grown with lysine 
supplementation but not without lysine supplementation after four 
subcultures (Figure 3c). Moreover, when bacteria were grown under 
selective pressure, the HindIII digestion pattern (HIVA DNA frag-
ment release) was detected in four out of five BCG.HIVA2auxo colonies. 
The BCG colony (#44) with low HIVA protein expression levels cor-
responded to the rBCG colony with altered restriction pattern, sug-
gesting some mutation in the expression cassette (not shown).
BCG.HIVA2auxo prime and MVA.HIVA boost regimen elicited HIV-
1-specific CD8+ and purified protein derivative-specific T-cell 
responses in mice
In this study, we have evaluated the specific HIV-1 T-cell immune 
responses in BALB/c mice after immunization with BCG.HIVA2auxo 
prime and MVA.HIVA boost (Figure 4a). The immunogenicity read-
out was focused on the P18–I10 epitope, an immunodominant CTL 
epitope derived from HIV-1 Env and H-2Dd murine restricted, which 
was fused to HIVA immunogen to evaluate the immunogenicity in 
mice (Figure 1a). Functional specific T cells in response to peptide 
stimulation were measured by intracellular cytokine staining and 
enzyme-linked immunosorbent spot (ELISPOT) assays.  We have 
observed that BCG.HIVA2auxo prime and MVA.HIVA boost elicited the 
highest proportion of P18–I10 epitope-specific CD8+ T-cells produc-
ing interferon-γ (IFN-γ), compared with the BCG wild-type priming 
and MVA.HIVA boost and with MVA.HIVA alone (Figure 4b). The 
quality of the elicited CD8+ T cells in terms of their ability to pro-
duce IFN-γ and tumor necrosis factor-α and to degranulate (surface 
expression of CD107a) in response to P18–I10 peptide stimulation 
was also investigated. We found that BCG.HIVA2auxo prime and MVA.
HIVA boost induced higher frequencies of trifunctional specific 
CD8+ T cells compared with the BCG wild-type priming and MVA.
HIVA boost and with MVA.HIVA alone (Figure 4c). The capacity of 
splenocytes from vaccinated mice to secrete IFN-γ was tested also 
by ELISPOT assay. We observed the highest frequency of specific 
cells secreting IFN-γ in mice primed with BCG.HIVA2auxo and boosted 
with MVA.HIVA (Figure 4d). Further experiments assessing different 
doses, routes, and immunization schedules should be performed.
BCG.HIVA2auxo elicited purified protein derivative–specific 
responses in mice. The capacity of splenocytes from vaccinated 
mice to secrete IFN-γ was tested by ELISPOT assays after overnight 
stimulation with the purified protein derivative antigen. The median 
spot-forming units per 106 splenocytes were similar in mice primed 
with BCG.HIVA2auxo or BCG wild type (196 and 222 spot-forming 
units/million splenocytes, respectively; Figure 4e).
BCG.HIVA2auxo prime and MVA.HIVA boost were well tolerated in 
mice
As shown in Figure 5b, the body mass was monitored over time 
and recorded to depict any adverse events and body mass loss due 
to vaccination. In order to detect vaccine-derived adverse events, 
a 12-week period between BCG-prime and MVA boost was estab-
lished for this trial (Figure 5a). Importantly, no statistically significant 
difference was observed between the vaccinated mice groups and 
the naive mice group in all monitored time points. Furthermore, 
between weeks 1 and 14, the body mass monitored in all vaccinated 
mice groups was found to lie between the mean ± 2 SD body mass 
Figure 2 Genetic characterization of the BCG.HIVA2auxo strain. 
(a) Enzymatic restriction analysis of p2auxo.HIVA plasmid DNA extracted 
from E. coli M15ΔglyA cultures (pre-BCG transformation) and from both 
the MS and WVS of BCG.HIVA2auxo cultures. Left side: E. coli cultures. Lanes 
1 and 5: molecular weight marker (1 kb plus; Invitrogen); lanes 2, 3, and 
4: AgeI, StuI, and XhoI digestion, respectively. Right side: BCG cultures. 
Lane 9: molecular weight marker (1 kb plus; Invitrogen); lanes 6, 7, and 
8 (MS): AgeI, StuI, and XhoI digestion, respectively. Lanes 10, 11, and 12 
(WS): AgeI, StuI, and XhoI digestion, respectively. (b) PCR analysis of HIVA 
DNA coding sequence using as template the cultures of BCG.HIVA2auxo MS 
(lane 2), WVS (lane 3), positive control plasmid DNA p2auxo.HIVA (lane 4), 
negative control, distilled water (lane 5), and molecular weight marker 
(lane 1). (c) PCR analysis of E. coli glyA DNA coding sequence using as 
template the cultures of BCG. HIVA2auxo MS (lane 2), WVS (lane 3), p2auxo 
plasmid DNA without HIVA immunogen insert (lane 4), positive control 
plasmid DNA p2auxo.HIVA (lane 5), negative control, distilled water 
































Engineering new mycobacterial vaccine design
N Saubi et al.
Molecular Therapy — Methods & Clinical Development (2014) 14017© 2014 The American Society of Gene & Cell Therapy
curve in naive mice (Figure 5b). It is also important to mention that 
no mice died during the trial, and no local adverse events and asso-
ciated systemic reactions were observed. 
DISCUSSION
Despite the progress made on prevention of mother-to-child HIV-1 
transmission, the development of a safe, effective, and affordable 
vaccine against HIV-1 and tuberculosis at the earliest time after birth 
to prevent breast milk HIV-1 transmission and childhood tuberculo-
sis is still a great challenge. In this study, we have constructed a novel 
E. coli–mycobacterial shuttle vector that contains the antibiotic-free 
plasmid selection system. It was stable in vivo for at least 7 weeks 
after mice immunization and was used to construct a marker-less 
BCG.HIVA2auxo vaccine suitable for good manufacturing practice. 
Overall, we have demonstrated that BCG.HIVA2auxo prime–MVA.HIVA 
boost regimen was well tolerated and induced HIV-1- and Mtb-
specific immune responses in mice. Thus, this strategy might be wor-
thy to pursue and for joining the global efforts to develop novel BCG 
vector–based vaccines for controlling tuberculosis and HIV/AIDS.
Even though, it has been described that antibiotics and antibiotic 
resistance genes have been traditionally used for the selection and 
maintenance of recombinant plasmids in hosts such as E. coli, their 
use has been considered unacceptable for clinical trials and product 
licensing. Several approaches have been pursued to replace antibi-
otics as selective markers for plasmid stability in bacteria, including 
plasmids harboring gene complementation of a host auxotrophy. 
In this study, we have constructed a novel E. coli–mycobacterial 
expression vector that employs an antibiotic resistance-free mecha-
nism for plasmid selection and maintenance based on the glyA 
for glycine auxotrophy complementation in E. coli and the lysA for 
lysine auxotrophy complementation in BCG.
The conventional methods for the identification of M. bovis BCG 
(BCG) vaccines, based on microscopic examination, biochemical 
tests, and morphological appearance, provided only limited sub-
strain differentiation and no specificity for BCG. The best way to 
identify different BCG substrains is by using molecular methods and 
genomic approaches. In this study, we have used the multiplex PCR 
assay described by Bedwell et al.22 to identify our BCG.HIVA2auxo vac-
cine candidate.  Resultant fingerprints after multiplex PCR assay of 
our BCG vaccine Pasteur substrain were consistent with the PCR pat-
tern of BCG Pasteur.
Méderlé et al.23 described the construction of rBCG strains coex-
pressing nef and gag (p26) from simian immunodeficiency virus 
(SIV) mac251. Extrachromosomal cloning into a replicative plasmid 
resulted in strains of low genetic stability that rapidly lost the plas-
mid in vivo. They observed that the genetic stability of integrative 
rBCG strains was much higher than that of replicative strains, both 
in vitro and in vivo mouse model. Borsuk et al. 24 reported the con-
struction of a BCG expression system using auxotrophic comple-
mentation as a selectable marker. Stability of the multicopy plasmid 
was evaluated during in vitro and in vivo growth of the rBCG in com-
parison to selection by antibiotic resistance. The new system was 
highly stable even during in vivo growth, as the selective pressure 
is maintained, whereas the conventional vector was unstable in the 
absence of selective pressure. These data are in concordance with 
our results. We have evaluated the in vitro stability of the p2auxo.
HIVA plasmid DNA harboring the auxotrophic complementation 
lysA gene. This plasmid was used to transform lysine auxotroph of 
BCG strain. All BCG.HIVA2auxo colonies that were grown on selective 
pressure maintained the vector in vitro and in vivo, whereas growth 
without selective pressure led to instability of the system in vitro due 
Figure 3 In vitro stability of the BCG.HIVA2auxo strain. (a) In vitro persistence 
of the p2auxo.HIVA in BCG lysA- grown for successive passages on 
selective (no lysine) or nonselective (supplemented with lysine) media. 
The percentage represents the cfu (titer) that maintained the vector 
containing the lysine complementing gene (grown on selective medium) 
versus to the total cfu. For BCG, the generation time is ~24 h. Thus, four 
subcultures represent ~30 BCG generations. The most representative 
of two experiments is shown. (b) Immunodot of BCG colonies lysates 
that were grown on selective (41, 42, 43, 44, and 45) and nonselective 
medium (1, 7, 13, 17, and 24); lysates of BCG wild type were used as 
negative control and lysates of BCG.HIVA2auxo WVS (before subculturing) 
as positive control. (c) HIVA PCR from purified plasmids of five individual 
colonies that were grown on selective (41, 42, 43, 44, and 45) and 
nonselective (1, 7, 13, 17, and 24) medium. Plasmid DNA p2auxo.HIVA 
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to plasmid loss. Regarding the functional stability of the heterolo-
gous HIVA gene, we found that the level of HIVA protein expression 
remained stable when bacteria were grown under selective pressure 
in four out of five colonies after four subcultures. Importantly, the 
BCG colony (#44) that showed low level of protein expression had 
also an altered HindIII digestion pattern, suggesting that it might 
be due to mutation or genetic rearrangement in the expression 
cassette. Contrarily, Borsuk et al.24 observed that the level of expres-
sion of lacZ remained stable with successive passages, and no gross 
modifications in vector structure were observed in five individual 
colonies when bacteria were grown under selective pressure. When 
we evaluated the in vivo plasmid stability, we found that 100% of 
Figure 4. Induction of HIV-1- and Mtb-specific T-cells responses by the BCG.HIVA2auxo prime–MVA.HIVA boost regimen. (a) Adult mice (7-weeks-old) were 
either left unimmunized or primed with 106 cfu of BCG.HIVA2auxo or BCG wild type (intradermally) and boosted with 106 pfu of MVA.HIVA (intramuscularly) 
5-weeks post-BCG inoculation. Mice were sacrificed 2 weeks later for T-cell analysis. (b) Analysis of IFN-γ vaccine elicited HIV-1-specific CD8+ T-cell 
responses. The frequencies of cells producing cytokine are shown. Data are presented as means (SEM; n = 8 for group 1, and n = 5 for groups 2, 3, and 4). 
(c) The functionality of vaccine-induced CD8+ T-cell responses was assessed in a multicolor intracellular cytokine staining assay. The group mean 
frequencies of single-, double-, or triple cytokine-producing P18–I10-specific cells are shown for the four vaccination groups. (d) Elicitation of specific 
T-cell responses was assessed in an ex vivo IFN-γ enzyme linked immunosorbent spot (ELISPOT) assay using the immunodominant P18–I10 CD8+ T-cell 
epitope peptide. The median spot-forming units (SFU) per 106 splenocytes for each group of mice (n = 8 for group 1, and n = 5 for groups 2, 3, and 4) as 
well as individual animal responses is shown. (e) Purified protein derivative (PPD)-specific T-cell responses elicited by BCG.HIVA2auxo. Immune responses 
to BCG were assessed in an ex vivo IFN-γ ELISPOT assay using PPD as the antigen. The median SFU per 106 splenocytes for each group of mice (n = 8 for 
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rBCG colonies recovered from the spleens of BALB/c mice 7 weeks 
after immunization maintained the plasmid.24 We did not evaluate 
the in vivo plasmid stability of the rBCG colonies without selective 
pressure because as stated by Pavelka et al.25, the Mycobacterium 
tuberculosis lysine auxotroph mc2 3026 vaccine strain was cleared 
from the lungs and spleens at day 30.
Our group and others have shown in murine and nonhuman pri-
mate studies that rBCG elicited cell-mediated responses against HIV-1 
and SIV antigens.13,26–29 However, a small proportion of these animal 
studies used rBCG strains in heterologous prime-boost regimens. 
Ami et al.30 have demonstrated that macaques vaccinated with rBCG-
expressing SIV gag and boosted with replication-defective poxvirus–
SIV gag, elicited effective protective immunity against mucosal chal-
lenge with SHIV KS661c. There is data showing that rBCG is a good 
priming vector in heterologous prime-boost vaccination regimens 
to enhance specific T-cell responses.5,31,32 In tuberculosis vaccine 
human trials, McShane et al.33 have demonstrated that vaccination 
with MVA-expressing Ag85A boosts preexisting antimycobacterial 
immune responses induced either by environmental mycobacteria 
or BCG vaccination, but the latest findings in a randomized, placebo-
controlled phase 2b trial have shown no efficacy against tuberculosis 
or M. tuberculosis infection in infants.34 We have previously shown 
in BALB/c mice that the inclusion of BCG.HIVA222 in a heterologous 
prime-boost regimen can prime and increase the HIV-1-specific T-cell 
immune responses elicited by MVA.HIVA and MVA.HIVA.Ag85A.5,16,26,35
There are few reports in the literature describing the safety and 
immunogenicity of rBCG-expressing HIV-1 antigens in neonatal 
mice. Ranganathan et al.4 have evaluated the immunogenicity in 
neonatal mice of three different recombinant attenuated Mtb strains 
expressing an HIV-1 envelope and showed that single dose immu-
nization rapidly generated HIV-1 and Mtb-specific T-cell immune 
responses. In a previous study, we showed in newborn mice that 
BCG.HIVACAT prime and MVA.HIVA boost increased the frequencies 
of specific CD8+ T-cells producing IFN-γ. We observed in newborn 
mice a lower level of HIV-1-specific T-cell immune responses com-
pared with adult mice. Rosario et al.36 have assessed the immuno-
genicity of the BCG.HIVA222 prime and MVA.HIVA boost regimen in 
newborn rhesus macaques and made similar observation.
Here, the vaccination with BCG wild type and BCG.HIVA2auxo strain 
induced BCG-specific responses in adult mice. Studies in neona-
tal mice have indicated that immune responses at birth are often 
biased toward the Th2 type and defective in the Th1 type, the central 
defense mechanism against intracellular pathogens.37–39 However, it 
has been described that BCG vaccination at birth induces a potent 
Th1-type immune response in humans and in mice.40The challenge 
for neonatal vaccinology is thus to develop, and promote at a global 
level, vaccines that could be safely administered soon after birth and 
would be effective after one or two early doses. According to our 
knowledge, only one report has been published about safety of anti-
biotic-free marker rBCG-based HIV-1 vaccine in mice.41 In this study, 
we have demonstrated in adult mice by the rate of body mass that 
BCG.HIVA2auxo prime and MVA.HIVA boost regimen was well tolerated.
We constructed and characterized a novel, safer, good labora-
tory practice–compatible BCG-vectored vaccine using prototype 
immunogen HIVA and tested the safety and immunogenicity of 
BCG.HIVA2auxo and MVA.HIVA in mice using the prime-boost regi-
men. In conclusion, the construction of this new E. coli–mycobac-
teria shuttle vector based on double auxotrophic complementa-
tion and antibiotic-free plasmid selection system will provide a 
new and improved methodological tool for mycobacterial vac-
cines design and development as a bacterial live recombinant 
vaccine vehicle. A BCG strain free of antibiotic resistance marker 
genes expressing a second-generation immunogen HIVconsv bet-
ter addressing the HIV-1 variability and escape42 is under construc-
tion. In addition, the same strategy will be used for other major 
pediatric pathogens such as malaria or tuberculosis, to prime pro-
tective response soon after birth.2,43
MATeRIAlS AND MeTHODS
Construction of BCG.HIVA2auxo strain by using an antibiotic-free  
plasmid selection system and expressing HIV-1 clade 
A immunogen
The E. coli–mycobacterial shuttle vector, plasmid pJH222.HIVA, was previ-
ously constructed in our laboratory.5 The aph gene, conferring kanamy-
cin resistance, was removed from pJH222.HIVA plasmid by SpeI digestion. 
Following aph gene excision, the glyA gene cassette was ligated into this 
plasmid and subsequently transformed into E. coli M15ΔglyA strain. Briefly, 
this cassette included the following elements: the α fragment, contain-
ing the weak constitutive P3 promoter; the β fragment containing the 
glyA gene, which encodes the enzyme serine hydroxymethyl transferase; 
and its own terminator sequence T1, a string of termination codons. In 
E. coli, the synthesis of intracellular glycine is carried out mainly by serine 
hydroxymethyl transferase enzyme. The αβT1 DNA fragment was amplified 
by PCR using the pQEαβT1FucA plasmid DNA as template.44 The primers 
were designed to incorporate SpeI and SmaI sites at both 5′ and 3′ termini 
of the amplified DNA fragment to be subcloned into pNEB193 vector (NEB, 
Ipswich, MA). Finally, the pNEB193.GlyA plasmid DNA was digested by SpeI, 
and the released αβT1 DNA fragment was cloned into pJH222.HIVA vector 
(lacking the kanamycin resistance gene after SpeI digestion), to generate 
the p2auxo.HIVA plasmid DNA.
Bacterial strains and cultures
E. coli Stbl2 cells (Invitrogen, Alcobendas, Spain) were grown in Luria-Bertani 
broth or Luria–Bertani agar plates (Sigma-Aldrich, St Louis, MO) at 30 °C. 
Luria–Bertani was supplemented with ampicillin (50 μg/ml). E. coli M15∆glyA 
cells (glycine auxotrophic)20 were grown in Luria-Bertani or minimal medium 
M9-derivative (Na2HPO4, 6.78 g/l; KH2PO4, 3 g/l; NaCl, 0.5 g/l; NH4Cl, 1 g/l, 
glucose, 10 g/l; MgSO4, 2 mmol/l; CaCl2, 0.1 mmol/l; thiamine, 0.1 g/l; FeCl3, 
Figure 5 BCG.HIVA2auxo prime and MVA.HIVA boost safety in adult mice. 
(a) Adult mice were either left unimmunized or immunized with 106 cfu 
of BCG wild type or BCG.HIVA2auxo by intradermal route and subsequently 
given a booster dose of 106 pfu of MVA.HIVA at week 12 by intramuscular 
route. (b) The body weight was recorded over time, and the mean for 
each group of mice is shown (n = 10 for group 1 and n = 5 for groups 2, 3, 
and 4). Data from naive mice are presented as mean ± 2 SD (n = 5, dashed 
lines). The weight differences between vaccinated and naive mice group 
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0.025 g/l; AlCl3·6H2O, 0.13 mg/l; ZnSO4·7H2O, 2.6 mg/l; CoCl2·6H2O, 0.47 mg/l; 
CuSO4·H2O, 4.6 mg/l; H3BO3, 0.03 mg/l; MnCl2·4H2O, 4.2 mg/l; NiCl2·6H2O, 
0.02 mg/l; Na2MoO4·2H2O, 0.06 mg/l), supplemented with glycine (70 μg/ml).  
The p2auxo.HIVA plasmid DNA was transformed by electroporation in gly-
cine auxotroph of E. coli cultures that were grown in M9-D broth or agar 
plates. On the other hand, the p2auxo.HIVA plasmid DNA was transformed 
by electroporation in a lysine auxotroph of BCG, kindly provided by Dr 
William Jacobs. Mycobacterial cultures were grown in Middlebrook 7H9 
broth medium or on Middlebrook agar 7H10 medium supplemented with 
albumin–dextrose–catalase (Becton Dickinson, Sparks, MD) and containing 
0.05% Tween 80. The l-lysine monohydrochloride (Sigma-Aldrich) was dis-
solved in distilled water and used at a concentration of 40 μg/ml. Escherichia 
coli and BCG electroporation conditions were described previously.5,45 
Commercial BCG Danish 1331 strain (Pfizer, New York, NY) was kindly pro-
vided by Dr Neus Altet and commercial BCG Connaught strain (ImmuCyst; 
Sanofi Aventis, Barcelona, Spain), from the Urology Department at Hospital 
Clínic de Barcelona.
Dot-blot analysis
Cell lysates of mid-logarithmic-phase BCG transformants were prepared by 
sonication and using a protein extraction buffer (50 mmol/l Tris–HCl pH 7.5, 
5 mmol/l EDTA, 0.6% sodium dodecyl sulfate) and 100× protease inhibitor 
cocktail (1 mg/ml aprotinin, 1 mg/ml E-64, 1 mg/ml leupeptin, 1 mg/ml pep-
statin A, 50 mg/ml pefabloc SC, and 10 ml dimethyl sulfoxide). Five micro-
liters of the protein extract was blotted onto a pretreated polyvinylidene 
difluoride membrane, and HIVA protein was detected using anti-Pk mono-
clonal antibody (MCA1360; AbD Serotec, Oxford, UK), with an enhanced che-
miluminescence kit (Pierce, Rockford, IL). To visualize the dots, the Typhoon 
8600 gel imaging system (GE Healthcare, Piscataway, NJ) was used.
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and 
western blot analysis
Cell lysates of mid-logarithmic-phase BCG transformants were prepared, 
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, 
and electroblotted. HIVA protein was detected using anti-Pk antibodies with 
an enhanced chemiluminescence kit (Pierce).
In vitro stability of BCG.HIVA2auxo strain
Four subcultures (~ 30 bacterial generations) of BCG.HIVA2auxo (working vac-
cine stock) harboring the p2auxo.HIVA plasmid DNA that contains the lysine 
complementing gene were grown in 7H9 broth with and without selection 
(l-lysine for ΔlysA strains). Subcultures were performed every 7 days, by 
transferring 100 µl of the stationary phase culture to 5 ml of fresh medium. 
The titer of the rBCG colonies on selective and nonselective 7H10 plates were 
compared in every subculture. To evaluate the functional stability of HIVA 
gene, the HIVA heterologous protein expression from five individual colo-
nies of the fourth subculture, that were grown on selective and nonselective 
medium, was determined by dot-blot analysis of BCG lysates and compared 
with the original BCG.HIVA2auxo working vaccine stock. In addition, the restric-
tion enzyme digestion pattern (HindIII–HindIII, HIVA DNA fragment cloning 
sites) and the PCR analysis of the HIVA DNA coding sequence from purified 
plasmids of five individual colonies of the fourth subculture as mentioned 
previously were determined to evaluate the plasmid’s structural stability.
In vivo stability of plasmid p2auxo.HIVA
The growth of BCG.HIVA2auxo and the in vivo stability of the extrachromo-
somal plasmid p2auxo.HIVA were established by the recovery of BCG.
HIVA2auxo colonies from the spleens after 7 weeks of mice immunization 
with 106 cfu of BCG.HIVA2auxo (i.d.) and 106 pfu of MVA.HIVA (i.m.). Spleens 
were homogenized and plated onto Middlebrook 7H10 medium, and the 
resulting BCG colonies were inoculated in 7H9 medium. The DNA coding 
sequence corresponding to HIVA immunogen was detected by PCR analysis, 
using the BCG liquid culture as a template. Specific primers were designed to 
amplify the DNA fragment encoding the chimeric 19-kDa lipoprotein signal 
sequence-HIVA protein.
Sample preparation for the multiplex PCR assay
For isolation of DNA from wild-type BCG and BCG.HIVA2auxo, 400 μl of myco-
bacterial culture were centrifuged at 13,000g for 10 minutes, at room 
temperature, the pellet was resuspended in 250 μl of distilled water and 
heated to 95 °C in a thermoblock for 15 minutes to lyse and inactivate vegeta-
tive bacterial forms. Finally, after 5 minutes of centrifugation at 10,000g, 5 μl 
of supernatant were used for the amplification reaction or stored at −20 °C. 
The commercial BCG strains were treated in a similar way, but in this case, 
400 µl of the reconstituted freeze-dried flask were used.
Multiplex PCR assay for M. bovis BCG substrain Pasteur 
identification
The multiplex PCR assay was previously described by Bedwell et al.22 For the 
PCR analysis, 5 µl of the mycobacterial DNA isolated from BCG.HIVA2auxo Pasteur 
and commercial BCG strains were used in a final reaction volume of 50 µl.
E. coli and mycobacterial plasmid DNA extraction
For E. coli plasmid DNA isolation, the QIAprep Spin Miniprep Kit was used 
following manufacturer’s instructions (Qiagen, Hilden, Germany). The BCG 
broth culture up to an optical density of 0.9 (600 nm) was used for mycobac-
terial plasmid DNA isolation. The QIAprep Spin Miniprep Kit (Qiagen) was 
used with following slight modifications: (i) prior to harvest (3 to 24 hours), 
sterile glycine at a final concentration of 1% (weight/volume) was added; (ii) 
the cell pellet was treated with the P1 buffer from the Miniprep Qiagen Kit, 
supplemented with 10 mg/ml of lysozyme (Sigma) and incubated at 37 °C 
overnight; (iii) the extraction column was treated with a 10-ml mixture of 
chloroform:isopropanol in 1:1 ratio.  The mycobacterial plasmid DNA iso-
lated was used for restriction enzyme analysis and PCR analysis.
Mice immunizations and isolation of splenocytes
Adult (7-weeks-old) female BALB/c mice were left either unimmunized or 
immunized with BCG.HIVA2auxo and were boosted with MVA.HIVA at doses, 
routes, and schedules outlined in the figure legends. On the day of sacri-
fice, individual spleens were collected, and splenocytes were isolated by 
pressing spleens through a cell strainer (Falcon; Becton Dickinson) using a 
5-ml syringe rubber plunger. Following the removal of red blood cells with 
ACK lysing buffer (Lonza, Barcelona, Spain), the splenocytes were washed 
and resuspended in complete medium (R10 (RPMI 1640 supplemented with 
10% fetal calf serum and penicillin–streptomycin), 20 mmol/l HEPES, and 
15 mmol/l 2-mercaptoethanol).
Peptides
For assessing the immunogenicity of HIVA in the BALB/c mice, the following 
peptides were used: H-2Dd-restricted epitope P18–I10 (RGPGRAFVTI).46 The 
purified protein derivative (Statens Serum Institute, Copenhagen, Denmark) 
was used to assess the immunogenicity induced by M. bovis BCG.
Ex vivo IFN-γ ELISPOT assay
The ELISPOT assay was performed using a commercial IFN-γ ELISPOT kit 
(Mabtech, Nacka Strand, Sweden) and following manufacturer’s instructions. 
The ELISPOT plates (MSISP4510, 96-well plates with polyvinylidene difluo-
ride membranes, Millipore, Billerica, MA) were coated with purified anti-
mouse IFN-γ capture monoclonal antibody diluted in phosphate-buffered 
saline to a final concentration of 5 µg/ml at 4 °C overnight. A total of 5 × 105 
fresh splenocytes were added to each well and stimulated with 2 μg/ml 
of the P18–I10 peptide or 5 μg/ml of purified protein derivative for 16 h at 
37 °C. Wells were washed 4× with phosphate-buffered saline 0.05% Tween 
20 and 2× with phosphate-buffered saline before incubating with 100-µl 
5-bromo-4-chloro-3-indoyl-phosphate/nitro blue tetrazolium substrate 
solution (Sigma). After 5–10 minutes, the plates were washed with tap water, 
dried, and the resulting spots counted using an ELISPOT reader (Autoimmun 
Diagnostika, Strassberg, Germany). 
Intracellular cytokine staining
One million splenocytes were added to each well of a 96-well round-bot-
tomed plate (Costar, Corning, NY) and pulsed with 2 μg/ml of P18–I10 pep-
tide and kept at 37 °C, 5% CO2 for 60 minutes, followed by the addition of 
GolgiStop (Becton Dickinson) containing monensin. After 5-hour incubation, 
reaction was terminated by storing the plate at 4 °C. The cells were washed 
with wash buffer (phosphate-buffered saline, 2% fetal calf serum, 0.01% 
azide) and blocked with anti-CD16/32 (BD Biosciences) at 4 °C for 30 minutes. 
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All subsequent antibody stains were performed using the same conditions. 
Cells were then washed and stained with anti-CD8-PerCP (BD Biosciences) 
and anti-CD107a-FITC, washed again, and permeabilized using the Cytofix/
Cytoperm kit (BD Biosciences). Perm/wash buffer (BD Biosciences) was used 
to wash cells before staining with anti-IFN-γ-APC and anti–tumor necrosis 
factor-α-PE (BD Biosciences). Cells were fixed with CellFIX (BD) and stored 
at 4 °C until analysis. All chromogen-labeled cells were analyzed in a Becton 
Dickinson FACScalibur, using the CellQuest software for acquisition (Becton 
Dickinson) and the Flow-Jo software (Tree Star, Ashland, OR) for analysis.
Statistical analysis
Immunogenicity data are shown as group means or group medians as well 
as individual responses. The body mass data are group means, and mean ± 
2 SD in naive mice group. Statistical significance was determined by analysis 
of variance. Statistical significance of the in vitro stability assay was assessed 
by a two-way analysis of variance (*P < 0.05; **P < 0.01). GraphPad Prism 5.0 
software was used.
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